Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma [NA]

View source ↗

Summary

A clinical trial is evaluating axicabtagene ciloleucel as first-line therapy for high-risk diffuse large B-cell lymphoma, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: Ruijin Hospital | Conditions: CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL) | NA | Status: NOT_YET_RECRUITING